449.74
price down icon2.19%   -10.07
after-market アフターアワーズ: 447.35 -2.39 -0.53%
loading
前日終値:
$459.81
開ける:
$459.57
24時間の取引高:
364.53K
Relative Volume:
1.12
時価総額:
$10.39B
収益:
$1.13B
当期純損益:
$-309.44M
株価収益率:
-35.14
EPS:
-12.8001
ネットキャッシュフロー:
$-275.41M
1週間 パフォーマンス:
-4.67%
1か月 パフォーマンス:
-15.00%
6か月 パフォーマンス:
-14.30%
1年 パフォーマンス:
+1.72%
1日の値動き範囲:
Value
$446.61
$462.62
1週間の範囲:
Value
$446.61
$478.85
52週間の値動き範囲:
Value
$393.61
$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
名前
Madrigal Pharmaceuticals Inc
Name
セクター
Healthcare (1052)
Name
電話
404-380-9263
Name
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
職員
915
Name
Twitter
@MadrigalPharma
Name
次回の収益日
2026-11-03
Name
最新のSEC提出書
Name
MDGL's Discussions on Twitter

Compare MDGL vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
MDGL icon
MDGL
Madrigal Pharmaceuticals Inc
449.74 10.39B 1.13B -309.44M -275.41M -12.80
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-24 再開されました Goldman Buy
2026-09-23 開始されました Citigroup Buy
2026-08-04 アップグレード Wolfe Research Peer Perform → Outperform
2026-07-27 開始されました Wells Fargo Overweight
2026-01-28 開始されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-05 アップグレード Cantor Fitzgerald Neutral → Overweight
2025-11-03 アップグレード BofA Securities Underperform → Neutral
2025-10-15 開始されました Truist Buy
2025-09-04 再開されました H.C. Wainwright Buy
2025-02-28 アップグレード B. Riley Securities Neutral → Buy
2025-02-27 繰り返されました H.C. Wainwright Buy
2024-06-28 開始されました Cantor Fitzgerald Neutral
2024-06-11 開始されました Wolfe Research Outperform
2024-04-22 開始されました BofA Securities Underperform
2024-03-15 アップグレード B. Riley Securities Sell → Neutral
2024-03-06 開始されました Citigroup Buy
2024-02-26 ダウングレード B. Riley Securities Neutral → Sell
2022-12-20 繰り返されました Oppenheimer Outperform
2022-12-19 繰り返されました H.C. Wainwright Buy
2022-12-19 繰り返されました Piper Sandler Overweight
2022-12-19 アップグレード Raymond James Underperform → Mkt Perform
2022-07-08 ダウングレード B. Riley Securities Buy → Neutral
2021-10-07 開始されました Jefferies Buy
2021-08-06 アップグレード BMO Capital Markets Market Perform → Outperform
2021-05-20 再開されました Goldman Buy
2020-11-24 再開されました Evercore ISI Outperform
2020-11-06 繰り返されました H.C. Wainwright Buy
2020-07-31 開始されました Piper Sandler Overweight
2020-06-05 開始されました BMO Capital Markets Market Perform
2020-05-05 開始されました Chardan Capital Markets Buy
2020-01-30 開始されました Canaccord Genuity Buy
2020-01-09 アップグレード UBS Neutral → Buy
2019-11-07 繰り返されました H.C. Wainwright Buy
2019-06-25 開始されました Stifel Hold
2019-06-10 アップグレード B. Riley FBR Neutral → Buy
2019-02-28 繰り返されました H.C. Wainwright Buy
2019-02-22 開始されました SVB Leerink Outperform
2019-01-23 開始されました UBS Neutral
2018-12-14 開始されました Wolfe Research Outperform
2018-12-12 開始されました B. Riley FBR Neutral
2018-11-19 ダウングレード Raymond James Mkt Perform → Underperform
2018-11-16 アップグレード Evercore ISI In-line → Outperform
2018-09-04 開始されました Citigroup Buy
2018-08-06 ダウングレード Goldman Buy → Neutral
2018-06-28 開始されました Raymond James Mkt Perform
すべてを表示

Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース

pulisher
Oct 07, 2026

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Zacks Investment Research

Oct 07, 2026
pulisher
Oct 07, 2026

Madrigal Pharmaceuticals stock gets fresh Rezdiffra data - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 06, 2026

A liver drug improved disease measures across several genetic risk groups - Stock Titan

Oct 06, 2026
pulisher
Sep 28, 2026

Under an automatic trading plan, director Paul Friedman proposes to sell shares in Madrigal Pharmaceuticals (MDGL). - Stock Titan

Sep 28, 2026
pulisher
Sep 21, 2026

Madrigal Grants Equity Awards to 27 New Employees - MyChesCo

Sep 21, 2026
pulisher
Sep 16, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 16, 2026
pulisher
Sep 16, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 16, 2026
pulisher
Sep 11, 2026

Understanding Momentum Shifts in (MDGL) - Stock Traders Daily

Sep 11, 2026
pulisher
Sep 11, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - stocktitan.net

Sep 11, 2026
pulisher
Sep 11, 2026

Madrigal Pharma CEO William John Sibold disposes of common shares worth $4.16 million - Bitget

Sep 11, 2026
pulisher
Sep 10, 2026

Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Sep 10, 2026
pulisher
Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria

Sep 10, 2026
pulisher
Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com UK

Sep 10, 2026
pulisher
Sep 10, 2026

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance

Sep 10, 2026
pulisher
Sep 10, 2026

Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq

Sep 10, 2026
pulisher
Sep 09, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - stocktitan.net

Sep 09, 2026
pulisher
Sep 07, 2026

September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq

Sep 07, 2026
pulisher
Sep 07, 2026

Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Sep 06, 2026

Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo

Sep 06, 2026
pulisher
Sep 02, 2026

Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus

Sep 02, 2026
pulisher
Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - manilatimes.net

Sep 02, 2026
pulisher
Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire

Sep 02, 2026
pulisher
Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance

Sep 02, 2026
pulisher
Aug 31, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 27% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews

Aug 31, 2026
pulisher
Aug 26, 2026

Madrigal Grants Stock Awards to 13 New Employees - MyChesCo

Aug 26, 2026
pulisher
Aug 25, 2026

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - Yahoo Finance

Aug 25, 2026
pulisher
Aug 24, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Report: Analysts See 31% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews

Aug 24, 2026
pulisher
Aug 21, 2026

When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛

Aug 21, 2026
pulisher
Aug 20, 2026

Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media

Aug 20, 2026
pulisher
Aug 20, 2026

Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView

Aug 20, 2026
pulisher
Aug 20, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 20, 2026
pulisher
Aug 20, 2026

Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - stocktitan.net

Aug 20, 2026
pulisher
Aug 20, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - stocktitan.net

Aug 20, 2026
pulisher
Aug 19, 2026

Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st

Aug 19, 2026
pulisher
Aug 19, 2026

Exploring 3 High Growth Tech Stocks In The US Market - Sahm

Aug 19, 2026
pulisher
Aug 18, 2026

Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo

Aug 18, 2026
pulisher
Aug 18, 2026

Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - stocktitan.net

Aug 18, 2026
pulisher
Aug 17, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews

Aug 17, 2026
pulisher
Aug 16, 2026

2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat

Aug 16, 2026
pulisher
Aug 15, 2026

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat

Aug 15, 2026
pulisher
Aug 15, 2026

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - Yahoo Finance

Aug 15, 2026
pulisher
Aug 14, 2026

Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo

Aug 14, 2026
pulisher
Aug 14, 2026

Madrigal Pharmaceuticals Inc (0JXI) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks

Aug 14, 2026
pulisher
Aug 13, 2026

Madrigal Pharmaceuticals Adds Renowned Leader to Board - The Globe and Mail

Aug 13, 2026
pulisher
Aug 13, 2026

Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Aug 13, 2026
pulisher
Aug 12, 2026

Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan - Kalkine Media

Aug 12, 2026

Madrigal Pharmaceuticals Inc (MDGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Madrigal Pharmaceuticals Inc (MDGL) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Sibold William John
President and CEO
Sep 11 '26
Sale
542.39
5,221
2,831,801
197,746
WILLIAM SIBOLD
Director
Sep 11 '26
Proposed Sale
533.12
5,221
2,783,420
0
William John Sibold
Officer and Director
Sep 09 '26
Proposed Sale
534.16
6,362
3,398,326
0
Sibold William John
President and CEO
Sep 09 '26
Sale
535.59
6,362
3,407,397
202,967
Kelley Shannon T
General Counsel
Aug 17 '26
Sale
514.97
664
341,940
11,474
Shannon Kelley
Officer
Aug 17 '26
Proposed Sale
507.56
664
337,020
0
Sibold William John
President and CEO
Jul 20 '26
Sale
547.30
2,500
1,368,253
209,329
William Sibold
Officer and Director
Jul 20 '26
Proposed Sale
553.48
2,500
1,383,700
0
Soergel David
Chief Medical Officer
Jun 01 '26
Sale
495.74
1,042
516,561
10,033
DAVID SOERGEL
Officer
Jun 01 '26
Proposed Sale
497.27
1,042
518,155
0
$54.68
price down icon 2.44%
$63.62
price down icon 2.53%
$9.18
price down icon 8.20%
$72.57
price up icon 0.07%
$316.58
price down icon 4.07%
$14.63
price down icon 4.81%
大文字化:     |  ボリューム (24 時間):